title: [In Process Citation].
authors.affiliation: , .
authors.forename: Werner
authors.initials: W
authors.lastname: Stingl
mesh_terms: D019380:Anti-HIV Agents / Q000191:economics / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D002219:Carbamates; D017046:Cost Savings; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004347:Drug Interactions; D004359:Drug Therapy, Combination / Q000191:economics; D015658:HIV Infections / Q000188:drug therapy / Q000191:economics; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000191:economics*; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D011759:Pyrrolidines; D000069474:Sofosbuvir / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D014633:Valine / Q000031:analogs & derivatives; D019562:Viral Load / Q000187:drug effects
chemical_list: D019380:Anti-HIV Agents; D000998:Antiviral Agents; D002219:Carbamates; D007093:Imidazoles; D011759:Pyrrolidines; D014633:Valine; C549273:daclatasvir; D000069474:Sofosbuvir